Lee's Pharmaceutical Holdings Limited (Lee's Pharm or “the Group”) is a public biopharmaceutical company with over 20 years operation in China's pharmaceutical industry. It is fully integrated with solid infrastructures in drug development, clinical development, regulatory, manufacturing, sales and marketing in China with global perspectives and currently markets 14 products in the PRC. Lee's Pharm focuses on several different areas such as cardiovascular and infectious diseases, dermatology, oncology, gynecology, ophthalmology and others. It has more than 30 products under different development stages stemming from both internal R&D as well as from the recent acquisition of licensing and distribution rights from various US, European and Japanese companies. In 2010, Lee’s Pharm ranked as Best Small-Cap Company in China (Rank 2nd) by Finance Asia. In September 2011, Lee's Pharm has been selected by Forbes as one of Asia's 200 Best Under A Billion Company (turnover less than US$1 billion). The mission of Lee's Pharm is to become a successful biopharmaceutical group in Asia providing innovative products to fight diseases and improve health and quality of life.
Sigma Tau Group, the leading research-based international pharmaceutical company based in Rome (Italy), is a strategic shareholder of Lee's Pharm. Sigma Tau's ongoing R&D activities and commercial know-how are complementary to the existing business activities of Lee's Pharm and will result in creating significant business synergies for Lee's Pharm.